Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Padmanee Sharma

Showing results (101-110 of 216) with videos related to

Pageof 22
Sort By:
Nature Communications|July 10, 2024
TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancerSwetha Anandhan, Shelley Herbrich, Sangeeta Goswami, et al.
International Journal of Clinical Oncology|June 21, 2019
Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analysesChikara Ohyama, Takahiro Kojima, Tsunenori Kondo, et al.
Journal for Immunotherapy of Cancer|December 18, 2019
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancerErminia Massarelli, Vincent K Lam, Edwin R Parra, et al.
Cancer Immunology Research|January 8, 2017
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 BlockadeCara L Haymaker, DaeWon Kim, Marc Uemura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2018
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric CancerYelena Y Janjigian, Johanna Bendell, Emiliano Calvo, et al.
Nature Cancer|August 31, 2023
Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockadeSangeeta Goswami, Deblina Raychaudhuri, Pratishtha Singh, et al.
Cancer Immunology Research|April 26, 2014
PD-L1 expression in triple-negative breast cancerElizabeth A Mittendorf, Anne V Philips, Funda Meric-Bernstam, et al.
Annals of Surgical Oncology|May 21, 2026
ASO Special Article: Proceedings of the Inaugural Joint US-India Cancer Dialogue: Accelerating Collaboration to Advance Cancer Prevention, Early Detection, Treatment, and CareCatharine Young, Dhananjay Tiwary, Maria Ekstrand, et al.
The Lancet. Oncology|October 14, 2016
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialPadmanee Sharma, Margaret K Callahan, Petri Bono, et al.
Biorxiv : the Preprint Server for Biology|January 9, 2026
Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint BlockadeMehdi Chaib, Muhammad Aminu, Shelley Herbrich, et al.
Pageof 22

Showing results (101-110 of 216) with videos related to

Sort By:
Pageof 22
Nature Communications|July 10, 2024
TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancerSwetha Anandhan, Shelley Herbrich, Sangeeta Goswami, et al.
International Journal of Clinical Oncology|June 21, 2019
Nivolumab in patients with unresectable locally advanced or metastatic urothelial carcinoma: CheckMate 275 2-year global and Japanese patient population analysesChikara Ohyama, Takahiro Kojima, Tsunenori Kondo, et al.
Journal for Immunotherapy of Cancer|December 18, 2019
High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancerErminia Massarelli, Vincent K Lam, Edwin R Parra, et al.
Cancer Immunology Research|January 8, 2017
Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 BlockadeCara L Haymaker, DaeWon Kim, Marc Uemura, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2018
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric CancerYelena Y Janjigian, Johanna Bendell, Emiliano Calvo, et al.
Nature Cancer|August 31, 2023
Myeloid-specific KDM6B inhibition sensitizes glioblastoma to PD1 blockadeSangeeta Goswami, Deblina Raychaudhuri, Pratishtha Singh, et al.
Cancer Immunology Research|April 26, 2014
PD-L1 expression in triple-negative breast cancerElizabeth A Mittendorf, Anne V Philips, Funda Meric-Bernstam, et al.
Annals of Surgical Oncology|May 21, 2026
ASO Special Article: Proceedings of the Inaugural Joint US-India Cancer Dialogue: Accelerating Collaboration to Advance Cancer Prevention, Early Detection, Treatment, and CareCatharine Young, Dhananjay Tiwary, Maria Ekstrand, et al.
The Lancet. Oncology|October 14, 2016
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialPadmanee Sharma, Margaret K Callahan, Petri Bono, et al.
Biorxiv : the Preprint Server for Biology|January 9, 2026
Macrophage-Dendritic Cell-T-Cell Tetrads Orchestrate Antitumor Immunity and Response to Checkpoint BlockadeMehdi Chaib, Muhammad Aminu, Shelley Herbrich, et al.
Pageof 22